Relevant bibliographies by topics / 1004 / Journal articles

Journal articles on the topic '1004'

To see the other types of publications on this topic, follow the link: 1004.
Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '1004.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Garg, Padma, Laura Coughlin, Julie Mirpuri, and Andrew Koh. "1004." Critical Care Medicine 43 (December 2015): 252–53. http://dx.doi.org/10.1097/01.ccm.0000474835.25164.03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Umei, Nao, Kazuaki Atagi, Hideo Okuno, Yasunori Otsuka, Yusuke Seino, Atsushi Ujiro, and Hideki Shimaoka. "1004." Critical Care Medicine 40 (December 2012): 1–328. http://dx.doi.org/10.1097/01.ccm.0000425217.24197.52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Doi, Kent, Masahiro Urata, Seiichiro Murata, Takehiro Matsubara, Minoru Ono, Eisei Noiri, and Naoki Yahagi. "1004." Critical Care Medicine 41 (December 2013): A252. http://dx.doi.org/10.1097/01.ccm.0000440241.08375.3e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Landis, Julia, Jessica Winter, Chris Droege, and Nicole Harger. "1004." Critical Care Medicine 42 (December 2014): A1602. http://dx.doi.org/10.1097/01.ccm.0000458501.52594.4b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Khan-Kernahan, Kevin, Deryk Chen, and Hariharan Seetharaman. "1004." Critical Care Medicine 47 (January 2019): 480. http://dx.doi.org/10.1097/01.ccm.0000551752.83642.a2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wilson, S. R., H. J. Jang, and T. K. Kim. "1004." Ultrasound in Medicine & Biology 32, no. 5 (May 2006): P2—P3. http://dx.doi.org/10.1016/j.ultrasmedbio.2006.02.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shahar Cohen, K. H., B. S. Teh, W. Mai, A. D. C. Paulino, B. Miles, D. Kadmon, and E. B. Butler. "1004." International Journal of Radiation Oncology*Biology*Physics 66, no. 3 (November 2006): S130. http://dx.doi.org/10.1016/j.ijrobp.2006.07.268.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Epstein, PaulR, and David Sharp. "1004." Lancet 342, no. 8878 (October 1993): 1004. http://dx.doi.org/10.1016/0140-6736(93)92872-q.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wolfler, A., G. Conti, M. Corbari, E. Rossetti, and I. Salvo. "ABSTRACT 1004." Pediatric Critical Care Medicine 15 (May 2014): 222. http://dx.doi.org/10.1097/01.pcc.0000449731.17749.99.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Weng, L., and G. D. Elliott. "C-1004." Cryobiology 69, no. 3 (December 2014): 513. http://dx.doi.org/10.1016/j.cryobiol.2014.09.333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Szentklaray, Maria. "Fall 1004." DMW - Deutsche Medizinische Wochenschrift 107, no. 35 (July 29, 2009): e131-e132. http://dx.doi.org/10.1055/s-0029-1236789.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Reizenstein, Jeremy F., and Benjamin Graham. "Algorithm 1004." ACM Transactions on Mathematical Software 46, no. 1 (April 28, 2020): 1–21. http://dx.doi.org/10.1145/3371237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Clariond, Jeannette L. "1004 Mina." Review: Literature and Arts of the Americas 52, no. 2 (July 3, 2019): 227–29. http://dx.doi.org/10.1080/08905762.2019.1681796.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Koch, H., and J. Castañer. "HA-1004." Drugs of the Future 10, no. 10 (1985): 815. http://dx.doi.org/10.1358/dof.1985.010.10.49652.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Benedict, S. L., S. Shen, M. Rosen, M. Naverette, X. Yang, and M. I. Cedars. "P-1004." Fertility and Sterility 86, no. 3 (September 2006): S506—S507. http://dx.doi.org/10.1016/j.fertnstert.2006.07.1402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

 . "1004 Beklonken." Zorg en Financiering 7, no. 7 (July 2008): 148. http://dx.doi.org/10.1007/bf03097240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Freitas, Maria Cecilia, Mikki Ozawa, Anh Nguyen, Nori Sasaki, Matthew Everly, Lorita M. Rebellato, and Paul I. Terasaki. "1004-LB." Human Immunology 74, no. 5 (May 2013): 485. http://dx.doi.org/10.1016/j.humimm.2012.11.037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Pyo, Chul-Woo, Wyatt Nelson, Yoon Soo Pyon, Ruihan Wang, Akiko Ishitani, Shu Shen, Anajane Smith, Shalini Pereira, and Daniel E. Geraghty. "1004-LBP." Human Immunology 75, no. 6 (June 2014): 479. http://dx.doi.org/10.1016/j.humimm.2014.01.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Takada, Kazuko, and Masatomo Hirasawa. "Streptococcus orisuis sp. nov., isolated from the pig oral cavity." International Journal of Systematic and Evolutionary Microbiology 57, no. 6 (June 1, 2007): 1272–75. http://dx.doi.org/10.1099/ijs.0.64741-0.

Full text
Abstract:
Five bacterial strains, designated as NUM 1001T, NUM 1002, NUM 1003, NUM 1004 and NUM 1005, were isolated from the oral cavities of pigs. Colonies grown on mitis salivarius agar were similar in morphology to those of mutans streptococci. The novel isolates were analysed biochemically using the Rapid ID 32 Strep microsystem, subjected to DNA–DNA hybridization with oral streptococci and had their 16S rRNA genes sequenced. On the basis of the phylogenetic and phenotypic evidence obtained, the strains represent a novel species of the genus Streptococcus, for which the name Streptococcus orisuis sp. nov. is proposed. The type strain is NUM 1001T (=JCM 14035T=DSM 18307T).
APA, Harvard, Vancouver, ISO, and other styles
20

Craffonara, Lois. "Die Grenze der Urkunde von 1002 / 1004 im heutigen Ladinien." Ladinia 22 (1998): 163–259. http://dx.doi.org/10.54218/ladinia.22.163-259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Manning, Pamela T., Benjamin J. Capoccia, Michael P. Rettig, Ronald R. Hiebsch, Robert W. Karr, John F. DiPersio, and William A. Frazier. "Dual-Function Anti-CD47mAbs Induce Tumor Cell Death and Promote Phagocytosis Resulting in Enhanced in Vivo Efficacy." Blood 124, no. 21 (December 6, 2014): 991. http://dx.doi.org/10.1182/blood.v124.21.991.991.

Full text
Abstract:
Abstract Recent success in immunomodulation of cancer has targeted immune checkpoints such as CTLA-4, PD-1 and PDL-1 to enhance adaptive immunity by stimulating production of tumor-selective, cytotoxic T cells. Anti-CD47mAbs enhance innate immunity by increasing the phagocytosis of tumor cells by macrophages leading to processing and presentation of tumor antigens to prime the adaptive T cell response. Many cancers, including hematologic cancers, up-regulate the expression of CD47 presumably to avoid immune destruction. Increased CD47 expression protects cancer cells from phagocytosis by sending a “don't eat me” signal to macrophages via SIRPalpha, an inhibitory receptor that prevents phagocytosis of CD47-bearing cells. CD47mAbs that block the CD47/SIRPalpha interaction (“blocking-only” mAbs) enhance phagocytosis of cancer cells in vitro. We have identified two CD47mAbs, Vx-1000 and Vx-1004, both of which block the CD47/SIRPalpha interaction and promote phagocytosis of tumor cells by macrophages equally well. However, Vx-1004 also has the unique property of killing cancer cells, but not normal blood cells, via a direct, cell-autonomous, cytotoxic mechanism. Therefore, Vx-1004 is a dual-function antibody. Vx-1004 selectively kills a variety of hematologic cancer cells in vitro, while Vx-1000, the blocking-only mAb, does not as assessed by annexin V staining and flow cytometry (Figure 1). In dose-response studies, cell death in leukemia cells was induced in 2 hrs by <1 ug="" vx-1004="" whereas="" normal="" peripheral="" blood="" mononuclear="" cells="" are="" resistant="" to="" the="" induction="" of="" cell="" death="" by="" following="" incubation="" with="" 10="" for="" 24="" hrs="" both="" these="" cd47mabs="" bind="" many="" species="" cd47="" including="" mouse="" and="" human="" p=""> To determine if the tumor-toxic activity of Vx-1004 confers enhanced efficacy in vivo compared to Vx-1000, we compared them in two mouse hematologic cancer models: murine acute promyelocytic leukemia (APL) and B cell lymphoma (BCL). Briefly, 1x106 GFP-labeled C57BL/6 APL cells were injected IV into wild-type C57BL/6 mice that were then treated IP with 0.4 mg/kg of either Vx-1000 or Vx-1004 on the day of tumor injection and on days 3 and 6 following tumor injection, a very low dose and limited dosing regimen. On day 25, the blood of these mice was analyzed for the number of circulating APL cells. As shown in Figure 2, Vx-1000 did not significantly reduce tumor burden compared to the control group. In contrast, Vx-1004 significantly reduced tumor burden compared to controls, demonstrating greater efficacy of the dual-function CD47mAb. In addition, enhanced efficacy of Vx-1004 compared to Vx-1000 was demonstrated in BCL (Figure 3). In this model, NSG mice were injected with 1x106 murine A20 lymphoma cells subcutaneously and then treated with 0.4mg/kg/day of the CD47mAbs IP for the first five days following tumor injection. In this model, Vx-1000 also failed to inhibit tumor growth compared to controls while Vx-1004 significantly reduced tumor burden at 35 days compared to both the control and Vx-1000 groups, nearly four weeks after treatment was stopped. These data demonstrate increased anti-cancer efficacy with a dual-function CD47mAb that not only blocks the CD47/SIRPalpha interaction to increase phagocytosis of cancer cells, but also selectively kills cancer cells. These studies indicate that dual-function CD47mAbs may have better anti-tumor activity in vivo and support their use in human clinical trials. Figure 1 Figure 1. Disclosures Manning: Corvus Pharmaceutical: Employment, Equity Ownership. Capoccia:Corvus Pharmaceutical: Employment, Equity Ownership. Hiebsch:Corvus Pharmaceutical: Employment, Equity Ownership. Karr:Corvus Pharmaceutical: Employment, Equity Ownership. Frazier:Corvus Pharmaceutical: Consultancy, Equity Ownership.
APA, Harvard, Vancouver, ISO, and other styles
22

Scatigna, André V., and Andreas S. Fleischmann. "1004. PHILCOXIA RHIZOMATOSA: Plantaginaceae: Gratioleae." Curtis's Botanical Magazine 38, no. 4 (October 11, 2021): 500–512. http://dx.doi.org/10.1111/curt.12415.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Gunter, Paul W., Massimo A. Bassi, Masha Ikromova, Jonathan Tsao, and Philip Gehrman. "1004 How Variable Is Sleep?" Sleep 42, Supplement_1 (April 2019): A404. http://dx.doi.org/10.1093/sleep/zsz067.1001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

SEGGEV, J. "1004 Radiocontrast media (RCM)-induced sialadenitis." Journal of Allergy and Clinical Immunology 105, no. 1 (January 2000): S341. http://dx.doi.org/10.1016/s0091-6749(00)91430-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Strasser, H., G. M. Pinggera, M. Mítterberger, H. Fritsch, M. Tiefenthaler, G. Konwalinka, M. Steinlechner, F. Frauscher, and G. Bartsch. "1004 Urinary incontinence — A muscular disease." European Urology Supplements 4, no. 3 (March 2005): 253. http://dx.doi.org/10.1016/s1569-9056(05)81008-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Spinelli, M., M. Citeri, L. Zanollo, and T. Redaelli. "1004 SOLIFENACIN IN NEUROGENIC OVERACTIVE BLADDER." European Urology Supplements 6, no. 2 (March 2007): 273. http://dx.doi.org/10.1016/s1569-9056(07)60999-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

 . "1004 Wettelijke Regels Opzegging Zorgverzekering Vereenvoudigd." Zorg en Financiering 5, no. 7 (July 2007): 76. http://dx.doi.org/10.1007/bf03092828.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

KIMURA, Yoshiharu, and Akio OCHI. "1004 Grooving of Beta-titanium Alloy." Proceedings of Conference of Chugoku-Shikoku Branch 2001.39 (2001): 357–58. http://dx.doi.org/10.1299/jsmecs.2001.39.357.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Richardson, Paul G., Constantine S. Mitsiades, Kathleen Colson, Eileen Reilly, Laura McBride, Judy Chiao, Linda Sun, et al. "Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma." Blood 110, no. 11 (November 16, 2007): 1179. http://dx.doi.org/10.1182/blood.v110.11.1179.1179.

Full text
Abstract:
Abstract Background: The histone deacetylase inhibitor vorinostat was approved by the United States FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following 2 systemic therapies. Vorinostat has also demonstrated promising preclinical activity in multiple myeloma. Patients and Methods: A Phase I trial of oral vorinostat 200, 250 or 300 mg bid for 5 days each week of a 4 week cycle or 200, 300, or 400 mg bid for 14 days/3 week cycle until progressive disease or intolerable toxicity was conducted. Patients with measurable, relapsed and/or refractory multiple myeloma with adequate hematologic, hepatic, and renal function were eligible. The objectives were to determine the maximum tolerated dose (MTD) on each of the schedules and assess activity and safety. Results: Thirteen patients (median age, 63 years; median 7 prior systemic therapies) were enrolled. The MTDs were not determined due to early termination of the study due to the decision of the sponsor. One patient (250 mg bid 5 days/week) developed dose-limiting toxicity (DLT) of grade 3 fatigue. There were no other DLTs and the maximum administered doses were 250 mg bid for 5 days each week of a 4-week cycle and 200 mg bid for 14 days/3-week cycle. Common drug-related adverse experiences included fatigue (69%), anorexia (62%), dehydration (46%), diarrhea (46%), and nausea (38%) and were mostly grade ≤ 2. Of 10 evaluable patients, 1 had a minimal response and 9 had stable disease (Table 1). Conclusions: Oral vorinostat was generally well tolerated at 250 mg bid for 5 days each week of a 4 week cycle or 200 mg bid for 14 days/3 week cycle in patients with advanced multiple myeloma. Modest activity was demonstrated in relapsed and/or refractory multiple myeloma and combination studies with other anti-myeloma agents are warranted. Table 1. Clinical outcomes of patients per EBMT Criteria* Allocation Number Age Baseline Myeloma Stage Prior Systemic Therapies Prior Bone Marrow Transplant Baseline β2-microglobulin On-study Duration (days) Best Response EBMT = European Group for Blood and Marrow Transplantation; MR = Minimal Response; ND = Not Determined; NE = Not Evaluable; SD = Stable Disease. *Cohorts 3, 5, and 6 were not initiated. Cohort 1 (200 mg twice daily x 5 days/week) 1001 55 III 12 1 ND 41 NE 1002 47 II 3 1 2.0 254 SD 1003 64 III 4 0 2.6 62 SD Cohort 2 (250 mg twice daily x 5 days/week) 1004 38 I 5 0 1.7 55 SD 1005 74 III 7 1 6.7 240 MR 1006 65 ND 7 2 3.3 74 NE 1007 67 ND 1 0 10.1 118 SD 1008 42 III 5 0 4.7 109 SD 1009 50 III 5 0 1.4 123 SD Cohort 4 (200 mg twice daily x 14 days/3 weeks) 861 69 IIIa 16 1 4.6 56 SD 862 63 IIIa 20 1 3.1 25 NE 863 61 IIIa 10 1 2.7 62 SD 864 71 IIIa 16 1 11.0 155 SD
APA, Harvard, Vancouver, ISO, and other styles
30

Mirski, Andrzej. "MANAGEMENT OF LANGUAGE OF COMMUNICATION IN THE FIRM." Scientific Journal of Polonia University 10, no. 3 (August 16, 2014): 67–79. http://dx.doi.org/10.23856/1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Gao, Wenda. "Immunological tolerance and its breakdown in Chagas heart disease role of parasitokines." Frontiers in Bioscience 8, no. 5 (2003): e218-227. http://dx.doi.org/10.2741/1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Gatz, Almut. "Florian Vogt, Die »Anleitung zur musikalischen Setzkunst« von Gottfried Heinrich Stölzel (1690–1749). Edition und Kommentar, Neumünster: von Bockel 2018." Zeitschrift der Gesellschaft für Musiktheorie [Journal of the German-Speaking Society of Music Theory] 16, no. 1 (2019): 137–42. http://dx.doi.org/10.31751/1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Krunic, Tanja, and Ljiljana Ruzic-Dimitrijevic. "Online Privacy Analysis and Hints for Its Improvement." Issues in Informing Science and Information Technology 5 (2008): 177–96. http://dx.doi.org/10.28945/1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Sclafani, Joseph A., Kamshad Raiszadeh, Ramin Raiszadeh, Paul Kim, Todd Doerr, Farhan Siddiqi, Ivan LaMotta, et al. "Validation and Analysis of a Multi-site MIS Prospective Registry Through Sub-analysis of an MIS TLIF Subgroup." International Journal of Spine Surgery 8 (2014): 4. http://dx.doi.org/10.14444/1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Агамагомедова, Саният, and Saniyat Agamagomedova. "CUSTOMS CONTROL AFTER THE RELEASE OF THE GOODS IN THE MEMBER STATES OF THE CUSTOMS UNION: COMPARATIVE ANALYSIS." Comparative Research In Law and Politics 1, no. 1 (September 1, 2013): 41–45. http://dx.doi.org/10.12737/1004.

Full text
Abstract:
At the present time customs control after the release of the goods is the priority for the customs authorities in consideration of Customs Union and the formation of the Eurasian Economic Space. The procedure of customs control after the release of the goods in the Customs Union of Russia, Belarus and Kazakhstan is regulated at the international, regional and national levels. Despite the processes of unification of the regulation of follow-up customs control in the Customs Union, some differences in the timing and the manner of its implementation still exist in the member states of the Customs Union. Harmonization and unification of regulation and enforcement in this area will improve the efficiency of customs control after the release of the goods in the Customs Union.
APA, Harvard, Vancouver, ISO, and other styles
36

Solis, Erecson Sipin. "Performance Evaluation of Different Tomato Lines Grown Organically in Catarman, Camiguin, Philippines." American Journal of Agricultural Science, Engineering, and Technology 6, no. 2 (July 21, 2022): 18–24. http://dx.doi.org/10.54536/ajaset.v6i2.125.

Full text
Abstract:
Tomato (Solanum lycopersicum) is considered an important crop, but local producers face difficulties in choosing the appropriate variety due to its diversity and ecological adaptability. In an effort to provide an alternative option of varieties and selection of suitable varieties, this research was conducted to evaluate the comparative performance of sixteen tomato varieties (11 AVRDC lines, five check varieties) at Tangaro, Catarman, Camiguin from January to April 2014 using randomized complete block design with three replications under field conditions. It was found out that plant height, days to 50% flowering, days to first harvest, plant vigor, percent survival, fruit yield, number of fruits, fruit weight, marketable yield, and resistance to tomato yellow leaf curl virus (TYLCV) showed significant differences among the various tomato varieties under trial except for the fruit size. Maximum plant height (65.30 cm) at 60DAT was recorded in T11 (AVTO 1002) followed by T8 (AVTO 1130). Most check varieties produced first flowers earlier compared to AVRDC lines, with T15 (CV4 M) at 20.67 days and consequently mature early by having its first harvest (56DAT) at least two days earlier except for T1 (AVTO 1009), T2 (AVTO 1003) and T3 (AVTO 9803). T12 (CV1 TD) exhibited a vigorous plant stand compared to AVRDC lines T2 (AVTO 1003) and T8 (AVTO 1130), which showed a weak stand at the first harvest. Checked varieties T12 (CV1 TD) has the highest percentage of survival, while T7 (AVTO 0101) and T10 (AVTO 9001) showed a percent plant survival statistically comparable to other check varieties. T14 (CV3 MF1) produced the most number of fruits, while T5 (AVTO 1004) produced the least. The highest computed yield per hectare was observed from T14 (CV3 MF1), while the lowest yield was computed from AVRDC line T9 (AVTO 1008). AVRDC lines T1 (AVTO 1009), T2 (AVTO 1003), and T3 (AVTO 9803) are most susceptible to TYLCV, while checked varieties were more resistant. Considering the overall performance, it was found out that the checked varieties performed well. AVRDC lines T10 (AVTO 9001) and T4 (AVTO 1173) were also promising for their growth and yield performance and resistance to TYLCV. However, the potential of these varieties is needed to be further tested for verification under different growing seasons to elicit substantial conclusions.
APA, Harvard, Vancouver, ISO, and other styles
37

"P-1004." In Vitro Cellular and Developmental Biology--Animal 41, ABSTRACT (2005): 27—A. http://dx.doi.org/10.1290/1543-706x(2005)41[27-aa:p]2.0.co;2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

"P-1004." In Vitro Cellular and Developmental Biology--Animal 42, ABSTRACT (2006): 21—A. http://dx.doi.org/10.1290/1543-706x(2006)42[21-aa:p]2.0.co;2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

YÜCETÜRK, Seher. "BOŞANMA SONRASI YAŞANANLAR: ÜSKÜDAR ÖRNEĞİ." Erciyes Akademi, December 9, 2022. http://dx.doi.org/10.48070/erciyesakademi.1177271.

Full text
Abstract:
Boşanma, çiftler arasında gerek genel sebeplerden gerek özel sebeplerden dolayı evliliğin yürümediği durumlarda, çiftlerin tek başına kimi zamanda karşılıklı anlaşarak birlikteliklerini sonlandırma halidir. Boşanma kararı öncelikli olarak erkeğin tekelindedir. Erkek istediği zaman karısını hiç sebep göstermeden –elbette durumun keyfiyete dönüşmesini engelleyecek dini ve hukuki yaptırımlar mevcuttur- boşayabilir. Boşanma hakkı erkek tarafından nikâh esnasında kadına verilmesi halinde kadın da dilediği zaman bu birlikteliği sonlandırabilir. Bundan başka kadınlar evliliklerini ciddi sebeplerden dolayı sürdürülebilir olmaktan çıkmış kabul ederler ve sonlandırmak isterlerse karşılıklı anlaşma yolu ile boşanma işine de girişebilirler. Çalışma sadece talâk hakkını kullanan erkeğin kadını boşama eylemi ele alınmıştır. Tek taraflı gerçekleştirilen boşamalarda boşanmanın maddi yükü erkeğin omzundadır ve kadına mehir, nafaka ve kisvesini ödemekle yükümlüdür. Ayrıca erkeklerin kadınları boşama eylemi ele alınırken doğal boşanma olarak gerçekleşen ölüm hali ve bu durumun erkek için ve kadının varisleri için doğurduğu davalarda çalışmaya konu edinilmiştir. Üsküdarlı kadınların erkeklerin kendilerini boşama kararı ile mahkemeye gittiklerinde boşama sırasında maddi haklarını talep ettikleri sicillere yansıyan davalardan anlaşılmaktadır. Çalışmada Üsküdar mahkemesine ait Siciller TDV ÜŞS NO:96 (1005-1006-1007-1008), 97(1001-1008), 98(985-1009), 99(1007-1009), 100(1007-1009), 101(1005-1010), 102(1009-1010), 103(1009-1010), 104(1010), 105(979-1011) on defter taranmış ve boşanma çeşitlerine ait Üsküdar mahkemesine yansıyan kayıtlar değerlendirilmeye alınmıştır.
APA, Harvard, Vancouver, ISO, and other styles
40

JOURNAL OF THE ILLUMINATING ENGINEERING INSTITUTE OF JAPAN 77, no. 11 (1993): plate1—plate4. http://dx.doi.org/10.2150/jieij1980.77.11_plate1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Kümmerle, Saskia. "§ 1004 BGB und Vindikationsanalogie?" Juristische Rundschau 2013, no. 2 (January 2013). http://dx.doi.org/10.1515/juru-2013-0047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

"Concurrent Technologies Corp., Booth 1004." Metal Finishing 99, no. 10 (October 2001): 22. http://dx.doi.org/10.1016/s0026-0576(01)81857-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

"10.1007/s11754-008-1004-3." CrossRef Listing of Deleted DOIs, 2010. http://dx.doi.org/10.1007/s11754-008-1004-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

"10.1007/s11755-008-1004-8." CrossRef Listing of Deleted DOIs, 2010. http://dx.doi.org/10.1007/s11755-008-1004-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

"10.1007/s10893-008-1004-2." CrossRef Listing of Deleted DOIs 1 (2000). http://dx.doi.org/10.1007/s10893-008-1004-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

"10.1007/s10720-008-1004-8." CrossRef Listing of Deleted DOIs 1 (2000). http://dx.doi.org/10.1007/s10720-008-1004-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

"10.1007/s11086-008-1004-4." CrossRef Listing of Deleted DOIs 1 (2000). http://dx.doi.org/10.1007/s11086-008-1004-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

"10.1007/s11819-008-1004-2." CrossRef Listing of Deleted DOIs, 2010. http://dx.doi.org/10.1007/s11819-008-1004-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

"10.1007/s11823-008-1004-2." CrossRef Listing of Deleted DOIs, 2010. http://dx.doi.org/10.1007/s11823-008-1004-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

"10.1007/s11826-008-1004-4." CrossRef Listing of Deleted DOIs, 2010. http://dx.doi.org/10.1007/s11826-008-1004-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic '1004' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography